Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
177
resultados
Última actualización
03/05/2025 [07:09:00]
Resumen de: US2025134097A1
Provided herein are compositions and related methods related to a class of formulation that can be applied once a day and still provide antimicrobial and/or antiviral protection during this period, thus exhibiting persistent sanitization to the user. In some embodiments, a hand cream with antimicrobial and/or antiviral protection can prevent against COVID-19 spread or infection. In some embodiments, the formulation comprises one or more of the following: benzalkonium chloride, zinc oxide, tributyl phosphate, soybean oil, and/or Triton X-100, or an analog, derivative, salt, or pharmaceutical equivalent thereof, with the formulation containing a predominance of water to prevent a greasy feel to the user.
Resumen de: WO2025090605A1
The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
Resumen de: US2025134989A1
The present invention relates to a novel vaccine composition for coronavirus infection-19 comprising a polymer-based mRNA carrier. Specifically, the present invention provides a vaccine composition comprising an mRNA carrier using a novel polymer capable of delivering a negatively charged genetic material such as mRNA, and the vaccine composition has excellent effects of enhanced in vivo immune activity such as high antibody formation ability and increased interferon-gamma production.
Resumen de: US2025134910A1
The present invention relates to a composition for treating coronavirus infection-19 (COVID-19), comprising taurodeoxycholic acid (TDCA) or a pharmaceutically acceptable salt thereof and an antiviral agent as active ingredients, it was confirmed that clinical symptoms were cured in patients with COVID-19 pneumonia who were administered a combination of a pharmaceutically acceptable salt of taurodeoxycholic acid as an inflammasome inhibitor and an antiviral agent, and thus this combination of taurodeoxycholic acid (TDCA) or a pharmaceutically acceptable salt thereof as an inflammasome inhibitor and an antiviral agent, holds promise as active ingredients in compositions for the prevention or treatment of lower respiratory tract infectious diseases, including COVID-19.
Resumen de: US2025134985A1
Provided herein, in some aspects, are methods for using the receptor-binidng domain (RBD) of the SARS-COV-2 S protein, including the the RBD-1, RBD-2, and/or RBD-3 regions, to identify therapeutics for the treatment of SARS-COV-2, developing a vaccine for the treatment or prevention of SARS-COV-2, and identifying a patient as being in need for a treatment for SARS-COV-2.
Resumen de: US2025134987A1
The current disclosure includes coronavirus vaccines that protect against pathogenic coronavirus species, as well as their variants. In certain embodiments, SARS-CoV-2 variant specific and multivalent coronavirus vaccines are described. The vaccines typically include a modified mRNA which encodes at least one coronavirus derived immunogen, such as a spike protein or a fragment thereof. The mRNA can be encapsulated into lipid nanoparticles or other carriers and formulated as pharmaceutical compositions which can be used to generate an immune response to coronavirus in a subject. The vaccines can be used to elicit potent B and T cell responses against SARS-CoV-2 variants and to confer protective immunity against SARS-CoV-2, as well as other pathogenic coronavirus species such as SARS-CoV and/or MERS-CoV.
Resumen de: US2025134945A1
Various embodiments provide a method of increasing immunity to a virus in a subject. The method can comprise administering to the subject one or more effective doses of an immune-enhancing natural-based composition; thereby stimulating increased expression one or more of IFN-γ, IL-1B, IL-6, IL-10, IL-12p40, IL-12p70, and TNF-α; inhibiting replication of the virus inside a cell of the subject, and preventing entry of virus into the cell. The method of increasing immunity can further comprise increasing immunity to an upper respiratory tract viral infection. The upper respiratory tract viral infection can be COVID-19. According to some aspects of the method of increasing immunity, the effective dose of the immune-enhancing natural-based composition comprises: 30-70 mgs of cyanidin-3-glucosides; 40-80 mgs of andrographolides; 75-125 mgs of ascorbic acid; 400-600 mgs of beta glucans; 300-500 mgs of polysaccharides; and 75-125 mgs of a blend of antioxidants.
Resumen de: US2025134944A1
The present invention provides a new tea fraction, which is made from the non-ethanol extract, and does not contain caffeine, epigallocatechin gallate (EGCG), gallic acid and catechin that are usually found in conventional tea extracts. The tea fraction has an efficacy in treating a lung fibrosis, particularly idiopathic pulmonary fibrosis (IPF), Covid-19 and long Covid.
Resumen de: US2025137007A1
Disclosed is an alternate method of prevention and treatment of diseases caused by viral pathogens of human being and animals including coronaviruses, influenza viruses, etc., by food supplementation or fortification of food with foodstuff derived from transgenic plants or parts thereof obtained from the presently disclosed transgenic plant seed. This method provides said transgenic plant seed, wherein the genome of said seed comprises an exogenous recombinant polynucleotide encoding a combination of polypeptides, which are carbohydrate binding proteins, particularly lectins that in combination as disclosed herein are combined in a manner to overcome potential toxicity caused by their transgenic expression and to lower the concentrations of each of the carbohydrate binding proteins when expressed as a part of the combination when compared to the individual transgenic expression of any of said carbohydrate binding proteins, and wherein said seed exhibit inhibition of viral replication and provide immunity against viral pathogens.
Resumen de: US2025138005A1
Diagnostic assay devices for detecting the presence of an analyte in a sample solution may comprise a microreactor configured to form a sample solution containing the analyte, flow the sample solution therethrough in a first direction to form an analyte-capture molecule complex, and transfer the sample solution to an absorbent strip pad configured to flow therethrough, in a second direction crossing the first direction, the sample solution including the analyte-capture molecule complex and indicate a presence of the analyte-capture molecule complex. The diagnostic devices may be used, for example, to identify the presence of SARS-Cov2, RSV, influenza A, influenza B or other pathogens in samples from patients.
Resumen de: US2025138011A1
Kits containing a multiplexed chemiluminescent detection system and microfluidics devices and methods for detecting the presence and/or concentration of anti-SARS-CoV-2 antibodies in a sample are disclosed. The kits, microfluidics devices, and methods utilize singlet oxygen-activatable chemiluminescent compounds in combination with two or more fluorescent molecules that emit light at different wavelengths. In certain non-limiting embodiments, the kits, microfluidics devices, and methods can distinguish between anti-SARS-CoV-2 antibodies generated in response to vaccination from anti-SARS-CoV-2 antibodies generated in response to infection.
Resumen de: US2025138004A1
An apparatus for detecting a biomarker comprises a droplet harvesting structure for converting breath vapor to a fluid droplet for forming a fluid sample and a testing system having a biomarker testing zone for receiving the fluid sample and detecting a biomarker. The droplet harvesting structure may include at least one of a hydrophobic field for receiving the breath vapor and forming the fluid droplet from the received breath vapor and hydrophilic channels for receiving the fluid droplet and channeling the fluid droplet towards the testing system. A fluid dam member may be provided disposed between the droplet harvesting structure and the biomarker testing zone.
Resumen de: AU2023372393A1
Monoclonal antibodies that specifically bind to and block the function of Fas ligand (FasL) are described. The FasL-specific antibodies can be used for the development of therapeutics for the treatment of diseases, disorders and conditions associated with the Fas/FasL signaling pathway, such as cancer, sepsis, ischemia-reperfusion injury, and coronavirus disease 2019 (COVID-19).
Resumen de: WO2025090048A1
The invention relates to an optimer-based electrochemical biosensor for use in the determination of SARS-CoV-2 S1 protein and Moxifloxacin as well as the method for its operation. The invention also includes an application of said method for the diagnosis of disease and the determination of drugs. In this context, SARS-CoV-2 S1 protein and Moxifloxacin were selected as target analytes and electrochemical analyses of these target analytes were performed using optimer-based procedure and electrochemical impedance spectroscopy technique.
Resumen de: WO2025089473A1
The present invention provides: a peptide set for quantifying and analyzing antigen proteins of individual subtypes from a specimen containing antigen proteins of a plurality of SARS-CoV-2 subtypes; and a method for simultaneously and quantitatively analyzing antigen proteins of SARS-CoV-2 subtypes according to types thereof, using same. The peptide set comprises one or more peptides specific to individual SARS-CoV-2 subtypes, selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 3, and a peptide common to SARS-CoV-2 subtypes, selected from SEQ ID NO: 4 or SEQ ID NO: 5.
Resumen de: WO2025086933A1
The present invention provides a new tea fraction, which is made from the non-ethanol extract, and does not contain caffeine, epigallocatechin gallate (EGCG), gallic acid and catechin that are usually found in conventional tea extracts. The tea fraction has an efficacy in treating a lung fibrosis, particularly idiopathic pulmonary fibrosis (IPF), Covid-19 and long Covid.
Resumen de: US2025134924A1
Compositions and methods for protecting against a wide spectrum of viral and bacterial infections, including Covid-19, and for treating established infection and infectious inflammation are described. The composition includes a novel combination of vitamins, minerals, nutraceuticals, and phytochemicals, which may be compounded as a pill, tablet, powder, capsule or liquid to be taken orally or via other administration routs one or more times per day, to serve as immune boosters, antibacterial agents, and antiviral agents along with providing anti-inflammatory effects in humans and animals.
Resumen de: WO2025090967A1
Provided herein are compositions and methods for treating musculoskeletal disorder such as arthritis, rheumatoid arthritis, osteoporosis, wound healing, corneal epithelial dystrophies and injuries, and cytokine storm with a molecule of formula: and one or more pharmaceutical acceptable excipients or salts; and methods for preventing and/or treating musculoskeletal disorder such as arthritis, rheumatoid arthritis, osteoporosis, wound healing, corneal epithelial dystrophies and injuries, and cytokine storm triggered by a coronavirus 2 (SARS-CoV-2) infection or fibrosis in a subject.
Resumen de: WO2025088482A1
The present invention relates to a composition, preferably a nutraceutical composition, for use in a method of treatment of subjects over 50 suffering from chronic fatigue, particularly due to: arthritis/chronic arthritis; heart disease; post-operative convalescence; depression; diabetes; fibromyalgia; chronic rheumatic diseases; stroke; cerebral ischemia; respiratory failure; chronic respiratory disease; allergic diseases; overweight/obesity; drug use, wherein said subjects are not suffering from Long-Covid/fatigue post Covid-19 syndrome.
Resumen de: US2025136668A1
The present disclosure relates to an antibody or antigen-binding fragment thereof that specifically binds to a spike protein of SARS-CoV-2. The present disclosure also relates to a pharmaceutical composition, a method for treating and/or preventing diseases and/or disorders caused by a coronavirus in a subject in need thereof, and a method for detecting a coronavirus in a sample.
Resumen de: EP4545971A2
The present invention relates to a peptide that specifically recognizes a protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or a portion thereof; a composition for preventing or treating SARS-CoV-2 infection, comprising the peptide; and a composition for detecting SARS-CoV-2, comprising the peptide.
Resumen de: EP4545970A2
The present invention relates to a peptide that specifically recognizes a protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or a portion thereof; a composition for preventing or treating SARS-CoV-2 infection, comprising the peptide; and a composition for detecting SARS-CoV-2, comprising the peptide.
Resumen de: AU2023286504A1
The present disclosure provides methods for treating Post-Acute Sequelae of Severe Acute Respiratory Syndrome (SARS)-CoV-2 infection (PASC) or one or more symptoms associated with said PASC, comprising administering to a subject in need or at risk thereof a pharmaceutical composition comprising a therapeutically effective amount of cyclobenzaprine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
Resumen de: EP4545559A2
The present invention is part of the field of genetic engineering, more specifically, in the field of production of anti-sars-cov-2 human monoclonal antibodies. The neutralizing human antibodies of the present application can be used in the therapy of COVID19, avoiding hospitalization and aggravation of infected people with a predisposition to develop severe disease. Persons who are not infected but at risk (health and safety professionals, and others) may benefit from preventive treatment. The present invention also relates to a pharmaceutical composition comprising anti-SARS-COV-2 human monoclonal antibodies, as well as a diagnostic kit and use thereof.
Nº publicación: EP4545969A2 30/04/2025
Solicitante:
CAREGEN CO LTD [KR]
Caregen Co., Ltd
Resumen de: EP4545969A2
The present invention relates to a peptide that specifically recognizes a protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or a portion thereof; a composition for preventing or treating SARS-CoV-2 infection, comprising the peptide; and a composition for detecting SARS-CoV-2, comprising the peptide.
BOPI
Sede Electrónica
